Unknown PHASE2 INTERVENTIONAL 1-arm NCT04814030

Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial (AIPD-1)

Transarterial Infusion of PD-1 Antibody Plus Chemoembolization and FOLFOX-based Chemtherapy for Unresectable BCLC C Stage HCC: a Single-arm, Phase 2 Clinical Trial

Sponsor: Sun Yat-sen University

Conditions Hepatocellular Carcinoma

Interventions PD-1 inhibitor

Updated 5 times since 2021 Last updated: Apr 21, 2021 Started: Apr 20, 2021 Primary completion: Dec 30, 2022 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04814030, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains ongoing. Sponsored by Sun Yat-sen University, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
May 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
May 2021 — May 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China